Teva Pharmaceuticals

Should I buy Teva Pharmaceuticals stock in 2025?

Is Teva Pharmaceuticals stock a buy right now?

Last update: 30 May 2025
Teva PharmaceuticalsTeva Pharmaceuticals
4.2
hellosafe-logoScore
Teva PharmaceuticalsTeva Pharmaceuticals
4.2
hellosafe-logoScore
P. Laurore
P. Laurore
Finance expert

As of late May 2025, Teva Pharmaceuticals (NYSE: TEVA) is trading at approximately $17.53 per share, with an average daily trading volume of 12.3 million shares, reflecting ongoing active investor engagement. While the stock has shown some volatility year-to-date (-20.46%), it has sustained a steady recovery over the past 6 to 12 months, aligning with broader sector trends in pharmaceuticals. Teva, a global leader in generic and specialty medicines, recently posted its ninth consecutive quarter of revenue growth, driven by standout performances from AUSTEDO and UZEDY, both surpassing forecasts in 2024. The pipeline remains robust, highlighted by key milestones such as FDA fast track designation for TEV-53408 in coeliac disease and successful progression of the anti-TL1A candidate Duvakitug. Market sentiment is constructively neutral, with technical indicators (MACD, Moving Averages) showing a slight positive bias. Notably, the consensus target price from over 33 national and international banks currently stands at $22.79, indicating broad confidence in the company's ongoing transformation and growth strategy. Within the pharmaceutical sector, Teva's innovation in biosimilars and continued adaptation make it an interesting candidate for careful consideration in a diversified portfolio.

  • Sustained revenue growth for nine consecutive quarters under new strategic direction.
  • Strong performance of flagship products AUSTEDO and UZEDY, both exceeding 2024 expectations.
  • Expanding biosimilars pipeline with 18 assets, enhancing long-term innovation prospects.
  • Successful cost management, with free cash flow of $2.07 billion in 2024.
  • Global industry leader in generics with a presence in 57 markets.
  • High debt burden remains, though showing continued improvement in recent quarters.
  • Meaningful exposure to geopolitical risks in Israel, managed proactively by management.
Teva PharmaceuticalsTeva Pharmaceuticals
4.2
hellosafe-logoScore
Teva PharmaceuticalsTeva Pharmaceuticals
4.2
hellosafe-logoScore
  • Sustained revenue growth for nine consecutive quarters under new strategic direction.
  • Strong performance of flagship products AUSTEDO and UZEDY, both exceeding 2024 expectations.
  • Expanding biosimilars pipeline with 18 assets, enhancing long-term innovation prospects.
  • Successful cost management, with free cash flow of $2.07 billion in 2024.
  • Global industry leader in generics with a presence in 57 markets.

Is Teva Pharmaceuticals stock a buy right now?

Last update: 30 May 2025
P. Laurore
P. Laurore
Finance expert
  • Sustained revenue growth for nine consecutive quarters under new strategic direction.
  • Strong performance of flagship products AUSTEDO and UZEDY, both exceeding 2024 expectations.
  • Expanding biosimilars pipeline with 18 assets, enhancing long-term innovation prospects.
  • Successful cost management, with free cash flow of $2.07 billion in 2024.
  • Global industry leader in generics with a presence in 57 markets.
  • High debt burden remains, though showing continued improvement in recent quarters.
  • Meaningful exposure to geopolitical risks in Israel, managed proactively by management.
Teva PharmaceuticalsTeva Pharmaceuticals
4.2
hellosafe-logoScore
Teva PharmaceuticalsTeva Pharmaceuticals
4.2
hellosafe-logoScore
  • Sustained revenue growth for nine consecutive quarters under new strategic direction.
  • Strong performance of flagship products AUSTEDO and UZEDY, both exceeding 2024 expectations.
  • Expanding biosimilars pipeline with 18 assets, enhancing long-term innovation prospects.
  • Successful cost management, with free cash flow of $2.07 billion in 2024.
  • Global industry leader in generics with a presence in 57 markets.
As of late May 2025, Teva Pharmaceuticals (NYSE: TEVA) is trading at approximately $17.53 per share, with an average daily trading volume of 12.3 million shares, reflecting ongoing active investor engagement. While the stock has shown some volatility year-to-date (-20.46%), it has sustained a steady recovery over the past 6 to 12 months, aligning with broader sector trends in pharmaceuticals. Teva, a global leader in generic and specialty medicines, recently posted its ninth consecutive quarter of revenue growth, driven by standout performances from AUSTEDO and UZEDY, both surpassing forecasts in 2024. The pipeline remains robust, highlighted by key milestones such as FDA fast track designation for TEV-53408 in coeliac disease and successful progression of the anti-TL1A candidate Duvakitug. Market sentiment is constructively neutral, with technical indicators (MACD, Moving Averages) showing a slight positive bias. Notably, the consensus target price from over 33 national and international banks currently stands at $22.79, indicating broad confidence in the company's ongoing transformation and growth strategy. Within the pharmaceutical sector, Teva's innovation in biosimilars and continued adaptation make it an interesting candidate for careful consideration in a diversified portfolio.
Table of Contents
  • What is Teva Pharmaceuticals?
  • How much is the Teva Pharmaceuticals stock?
  • Our full analysis on Teva Pharmaceuticals stock
  • How to buy Teva Pharmaceuticals stock in Ireland?
  • Our 7 tips for buying Teva Pharmaceuticals stock
  • The latest news about Teva Pharmaceuticals
  • FAQ
  • On the same topic

What is Teva Pharmaceuticals?

IndicatorValueAnalysis
🏳️ NationalityIsraelCompany based in Israel, offering strong presence across 57 international markets.
💼 MarketNYSE (New York Stock Exchange)Listed on NYSE, providing good liquidity and access for global investors, including those in IE.
🏛️ ISIN codeUS8816242098US ISIN for ADRs allows straightforward trading via international brokerage accounts.
👤 CEORichard FrancisDriving the “Pivot to Growth” strategy, showing operational turnaround and consistent performance.
🏢 Market cap$20.35 billionLarge-cap status reflects strong scale and steady investor interest.
📈 Revenue$16.54 billion (2024); $16.8–$17.4B expected (2025)Revenue growing steadily, with forecasts showing further expansion in 2025.
💹 EBITDA$4.78 billion (2024); $4.5–$5.0B expected (2025)Robust EBITDA provides operating flexibility and supports continued investment in innovation.
📊 P/E Ratio (Price/Earnings)N/A (negative; losses on GAAP basis)No P/E due to negative earnings, but strong non-GAAP profits and improving trend are positives.
🏳️ Nationality
Value
Israel
Analysis
Company based in Israel, offering strong presence across 57 international markets.
💼 Market
Value
NYSE (New York Stock Exchange)
Analysis
Listed on NYSE, providing good liquidity and access for global investors, including those in IE.
🏛️ ISIN code
Value
US8816242098
Analysis
US ISIN for ADRs allows straightforward trading via international brokerage accounts.
👤 CEO
Value
Richard Francis
Analysis
Driving the “Pivot to Growth” strategy, showing operational turnaround and consistent performance.
🏢 Market cap
Value
$20.35 billion
Analysis
Large-cap status reflects strong scale and steady investor interest.
📈 Revenue
Value
$16.54 billion (2024); $16.8–$17.4B expected (2025)
Analysis
Revenue growing steadily, with forecasts showing further expansion in 2025.
💹 EBITDA
Value
$4.78 billion (2024); $4.5–$5.0B expected (2025)
Analysis
Robust EBITDA provides operating flexibility and supports continued investment in innovation.
📊 P/E Ratio (Price/Earnings)
Value
N/A (negative; losses on GAAP basis)
Analysis
No P/E due to negative earnings, but strong non-GAAP profits and improving trend are positives.

How much is the Teva Pharmaceuticals stock?

The price of Teva Pharmaceuticals stock is declining this week. As of now, TEVA shares are trading at $17.53, marking a 3.42% drop over the past 24 hours and a 3.36% decrease across the week. The company's market capitalisation stands at $20.35 billion, with a 3-month average daily volume of 12.3 million shares. The price/earnings (P/E) ratio is currently not applicable due to recent losses, and no dividend yield is offered. TEVA’s beta is 0.63, suggesting relatively low volatility compared to the wider market—an aspect that may appeal to cautious investors monitoring stability within the pharmaceutical sector.

Compare the finest brokers in Ireland and find the best one for you!Compare brokers

Our full analysis on Teva Pharmaceuticals stock

Having closely analysed Teva Pharmaceuticals' (NYSE: TEVA) latest quarterly and annual results, as well as its share price evolution over the last three years, we have leveraged a suite of data-driven approaches encompassing financial ratios, proprietary technical signals, real-time market dynamics, and detailed peer benchmarking. Synthesising these insights through our advanced algorithms, we arrive at a crucial consideration for 2025: why might Teva Pharmaceuticals stock once again become a strategic entry point into the ever-evolving global healthcare and biotechnology sector?

Recent Performance and Market Context

Teva has displayed resilient stock behaviour despite episodic intraday volatility, currently trading at $17.53 (as of May 30th, 2025). Over the past 52 weeks, TEVA shares have oscillated between $12.47 and $22.80, revealing sizeable upside potential from the current price, especially given the consensus analyst target of $23.12. After a modest 6.57% gain over the past year and a 4.47% rise in the last six months, the stock nevertheless finds itself down 20.46% year-to-date—an apparent lag that, on closer analysis, highlights a possible opportunity amid sector rotation and investor repositioning.

Crucially, Teva reported its ninth consecutive quarter of revenue growth through Q1 2025. The health of its innovative product portfolio, especially the outperformance of treatments like AUSTEDO ($1.6bn revenue in 2024, ahead of expectations) and UZEDY ($117m in 2024 versus a $100m target), has provided a robust fundamental platform. Meanwhile, the pharmaceutical sector continues to enjoy a favourable macro backdrop, with global demand for generic and specialty medications on the rise amid regulatory tailwinds in the US and EU. For IE investors, exposure to global players like Teva offers appealing diversification in both currency and market dynamics.

Technical Analysis

Teva’s technical landscape is currently neutral with an emerging bullish tilt. The 14-day Relative Strength Index (RSI) stands at 49.05—firmly neutral but close to levels where upward momentum often builds. The MACD (+0.09) flashes a buy signal, indicating a favourable shift in price momentum, while the Stochastic (9,6) at 17.37 places the stock in oversold territory—suggesting that downside risk is becoming increasingly limited.

  • 5-day MA: $17.49 (buy signal)
  • 50-day MA: $17.20 (buy signal)
  • 100-day MA: $17.22 (buy signal)
  • 200-day MA: $16.28 (buy signal)

The most prominent technical support is identified at $17.34 (near today's low), while resistance stands at $18.28 (today's high). This compact trading range highlights a consolidation phase, typically the precursor to renewed strength if catalysts unfold.

Overall, technical indicators reinforce the notion that Teva may be entering a new bullish phase, and that the share is well-supported for accumulation near recent lows.

Fundamental Analysis

Teva’s transformation over the past two years is underpinned by operational excellence and strategic vision. Annual revenue for 2024 reached $16.54bn (+6% in local currencies), and adjusted EBITDA climbed to $4.78bn. Notably, Q4 free cash flow was $790m, and full-year free cash flow hit $2.07bn, indicating strong underlying performance.

While trailing earnings (TTM EPS: -$1.15) remain negative due to legacy challenges, the company’s non-GAAP EPS for 2024 stood at an impressive $2.49—comfortably beating expectations and demonstrating the underlying health of core operations. The lack of a current dividend redistributes resources towards R&D and debt reduction, both prudent at this phase of Teva's evolution.

Market Capitalisation$20.35bn
Historic sector multiplesForward-looking valuation is compelling despite negative trailing P/E
PEG RatioNot available due to negative earnings, but robust EBITDA and sales multiples
Historic sector multiples
$20.35bn
Forward-looking valuation is compelling despite negative trailing P/E
PEG Ratio
$20.35bn
Not available due to negative earnings, but robust EBITDA and sales multiples

Teva’s structural strengths should not be underestimated:

  • Innovation pipeline: 18 biosimilar assets in development.
  • Market share: Leadership in generics across the US and Europe.
  • Brand: Recognised as a trusted supplier to healthcare systems globally.
  • Management: Strategic “Pivot to Growth” is reaffirmed each quarter, under CEO Richard Francis.

Volume and Liquidity

Teva is consistently one of the most actively traded pharmaceutical stocks on the NYSE, with a 3-month average daily trading volume of 12.3 million shares. This high liquidity provides a dynamic environment for both retail and institutional investors, translating to orderly price discovery and tight bid-ask spreads. The outstanding float (1.15bn shares) supports a market that can absorb significant inflows without distorting valuation, and also allows for relatively efficient portfolio rebalancing—an appealing characteristic for active investors in IE seeking overseas equities.

Catalysts and Positive Outlook

  • Product Innovation: AUSTEDO and UZEDY are rapidly becoming blockbuster anchors.
  • Pipeline Expansion: The expected launch of SELARSDI and positive FDA ‘Fast Track’ designation for TEV-53408 (celiac disease) are set to drive news flow.
  • Clinical Milestones: Duvakitug (anti-TL1A) is moving into pivotal Phase 3 trials in 2025 after promising Phase 2B results.
  • Biosimilars: With 18 assets progressing, Teva is well-placed to address the vast “patent cliff” opportunity as leading biologics go off-patent.
  • Operational Momentum: Nine consecutive quarters of growth, ongoing deleveraging (total debt falling from elevated levels), and improved free cash generation.

The sector context also remains constructive. Global health expenditure continues to trend higher, and innovation in specialty generics and biosimilars remains a coveted growth avenue—particularly as payors and health services worldwide seek cost containment and improved outcomes.

Investment Strategies

Teva’s risk-reward balance appears increasingly favourable across investment horizons:

  • Short-Term Entry
    • Recent pullback to strong technical support at $17.34
    • Oversold short-term indicators and impending catalyst events (product launches, regulatory decisions)
    • Attractive swing trade potential as price compresses towards the lower end of the 2025 analyst target range
  • Medium-Term Positioning
    • Building a position ahead of major pipeline announcements (SELARSDI launch, Duvakitug Phase 3)
    • Outlook for sustained EBITDA and free cash margin expansion
    • Potential for positive earnings surprises as analyst estimates remain conservative
    • Re-rating opportunity as sector sentiment rotates back into undervalued growth names
  • Long-Term Strategy
    • Exposure to secular innovation in global healthcare, with a deeply diversified product base and geographic reach (57 markets, ~37,000 employees)
    • Leadership in generics and biosimilars, well-suited for multiyear growth as demographic and regulatory trends remain supportive
    • Consistent deleveraging and operational discipline increase resilience and optionality for value creation

For investors seeking a portfolio anchor in global pharma, accumulation near the current technical floor could be prudent ahead of a possible multi-quarter recovery.

Is it the Right Time to Buy Teva Pharmaceuticals?

Synthesising the analysis, Teva Pharmaceuticals emerges as a company decisively transitioning from a legacy turnaround story to a pioneering global player with clear leadership in generics, specialty pharmaceuticals, and biosimilars. The recent string of outperformance, robust pipeline maturation, and strategic focus under CEO Richard Francis are fundamentally altering the risk/reward proposition.

  • Multiple consecutive quarters of earnings outperformance and revenue growth
  • Significant new product catalysts (AUSTEDO, UZEDY, SELARSDI, Duvakitug)
  • Expanding biosimilars and innovation pipelines
  • Strong liquidity, institutional ownership, and high trading volume
  • Valuation that remains attractive relative to peers despite visible growth momentum

While investors should remain mindful of moderate risks such as the company’s leverage (albeit on a downward trajectory) and its geopolitical exposure, these appear well-priced into the market. Analyst consensus is converging towards a more constructive stance, and recent upgrades reflect an emerging appreciation for Teva’s compelling growth profile.

In conclusion, Teva Pharmaceuticals seems to represent an excellent opportunity for investors looking to gain exposure to the convergence of healthcare innovation and global market diversification. With fundamentals and technicals aligning favourably and a pipeline brimming with near-term and long-term catalysts, Teva may be entering a fresh bullish phase that merits careful consideration as part of a diversified portfolio. For those seeking quality at a cyclical low, the current environment provides a strategic window to participate in the company’s renewed ascent.

How to buy Teva Pharmaceuticals stock in Ireland?

Buying shares in Teva Pharmaceuticals (ticker: TEVA), a leading global pharmaceutical company, is now simple and secure for Irish investors thanks to regulated online brokers. You can invest by purchasing actual Teva shares (“spot buying”) or trading using Contracts for Difference (CFDs), each offering distinct benefits. Spot buying means you own the shares directly, suitable for long-term investors, while CFDs allow you to speculate on price movements with leverage—ideal for short-term strategies. Below, we detail these two main approaches, with a useful broker comparison further down this page.

Spot Buying

A cash or spot purchase of Teva Pharmaceuticals stock means you buy real TEVA shares on the New York Stock Exchange, becoming a shareholder with voting rights and potential for capital gains. Most Irish-friendly brokers charge a fixed commission per order—typically between $4 and $10 (or the euro equivalent), often around $5 for modest amounts.

icon

Example

Suppose the Teva share price is $17.53. With a $1,000 investment and a $5 brokerage fee, you could buy approximately 56 shares ($1,000 - $5 = $995; $995 ÷ $17.53 ≈ 56 shares).

Gain scenario: If the share price rises by 10%, your holding is now worth about $1,100 (56 × [$17.53 × 1.10]). Result: +$100 gross gain, or +10% on your initial investment (excluding taxes and currency conversion if applicable).

Trading via CFD

CFD trading allows you to speculate on the price changes of Teva Pharmaceuticals without owning the actual shares. CFDs typically require a lower capital outlay and offer leverage (often up to 5:1 for EU investors), amplifying both potential gains and risks. The main fees are the spread (the difference between buy and sell price) and overnight financing if you hold positions beyond a single day.

icon

Example

You open a CFD position on Teva shares with $1,000 using 5x leverage, giving you market exposure of $5,000.

Gain scenario: If Teva’s price rises by 8%, your leveraged position grows by 8% × 5 = 40%. On your $1,000 initial margin, that’s a $400 gross gain (before subtracting spread and any overnight financing fees).

Final Advice

Before investing, carefully compare brokers’ fees, account types, and regulatory safeguards—these can impact both your costs and security as an Irish investor. Your chosen method will depend on your goals: spot buying suits long-term wealth building, while CFDs are aimed at experienced investors seeking short-term opportunities. A detailed broker comparison is available further down this page to help you make an informed, confident choice.

Compare the finest brokers in Ireland and find the best one for you!Compare brokers

Our 7 tips for buying Teva Pharmaceuticals stock

📊 Step📝 Specific tip for Teva Pharmaceuticals
Analyse the marketExamine Teva’s recent 9 consecutive quarters of growth and its leadership in generics and biosimilars, highlighting resilient performance and positive outlook for 2025.
Choose the right trading platformOpt for an Irish or EU-regulated broker that provides access to NYSE for purchasing TEVA shares in USD, ensuring compliance and low transaction fees.
Define your investment budgetConsider Teva’s moderate volatility and set an investment amount you are comfortable with, mindful of your wider portfolio and the absence of dividends.
Choose a strategy (short or long term)A long-term approach suits Teva, given its continuous transformation, strong pipeline in biosimilars, and the company’s focus on sustainable growth.
Monitor news and financial resultsKeep up to date with Teva’s quarterly earnings, product pipeline updates like AUSTEDO and UZEDY, and regulatory news that can quickly impact share price.
Use risk management toolsPlace stop-loss orders just below support levels (e.g., $17.34) to manage downside risk and protect your capital from sudden market movements.
Sell at the right timePlan to take profits near resistance points (e.g., around $18.28 or when targets are met) or if news signals a shift in Teva’s market prospects.
Analyse the market
📝 Specific tip for Teva Pharmaceuticals
Examine Teva’s recent 9 consecutive quarters of growth and its leadership in generics and biosimilars, highlighting resilient performance and positive outlook for 2025.
Choose the right trading platform
📝 Specific tip for Teva Pharmaceuticals
Opt for an Irish or EU-regulated broker that provides access to NYSE for purchasing TEVA shares in USD, ensuring compliance and low transaction fees.
Define your investment budget
📝 Specific tip for Teva Pharmaceuticals
Consider Teva’s moderate volatility and set an investment amount you are comfortable with, mindful of your wider portfolio and the absence of dividends.
Choose a strategy (short or long term)
📝 Specific tip for Teva Pharmaceuticals
A long-term approach suits Teva, given its continuous transformation, strong pipeline in biosimilars, and the company’s focus on sustainable growth.
Monitor news and financial results
📝 Specific tip for Teva Pharmaceuticals
Keep up to date with Teva’s quarterly earnings, product pipeline updates like AUSTEDO and UZEDY, and regulatory news that can quickly impact share price.
Use risk management tools
📝 Specific tip for Teva Pharmaceuticals
Place stop-loss orders just below support levels (e.g., $17.34) to manage downside risk and protect your capital from sudden market movements.
Sell at the right time
📝 Specific tip for Teva Pharmaceuticals
Plan to take profits near resistance points (e.g., around $18.28 or when targets are met) or if news signals a shift in Teva’s market prospects.

The latest news about Teva Pharmaceuticals

Teva Pharmaceuticals has maintained nine consecutive quarters of revenue growth, affirming the effectiveness of its "Pivot to Growth" strategy. This sustainable expansion, confirmed most recently in Q1 2025, has been underpinned by robust sales across both generics and specialty products, demonstrating resilience in global markets, including Ireland, where Teva maintains a direct presence supporting local healthcare infrastructure. The company’s ongoing transformation under CEO Richard Francis, especially through operational refinements and a sharpened commercial focus, provides a constructive backdrop for continued recovery and positions Teva as a stable pharmaceutical partner for Irish healthcare providers.

Key innovative products, particularly AUSTEDO and UZEDY, have recorded performance exceeding expectations, driving strong momentum across developed markets. In 2024, AUSTEDO generated over $1.6 billion in revenues and UZEDY achieved $117 million—both surpassing internal targets—with AUSTEDO’s success reinforcing Teva’s footing in neurology and movement disorders, areas of significant therapeutic need in Ireland. This success story is relevant for the Irish market, as AUSTEDO is increasingly prescribed for Huntington’s disease and tardive dyskinesia, with reimbursement pathways aligning to HSE guidelines. The company’s strong specialty portfolio, coupled with a growing biosimilar pipeline, enhances access to affordable medicines for regional healthcare systems.

Teva has recently achieved a crucial regulatory milestone, securing US FDA Fast Track designation for TEV-53408 in celiac disease, alongside positive Phase 2B results for Duvakitug (Anti-TL1A). This advancement is significant for Irish analysts, as Ireland faces one of Europe’s highest celiac prevalence rates, and regulatory accelerations in the US are likely to influence the speed of European Medicines Agency (EMA) reviews. Such progress underscores Teva’s rising innovation credentials, potentially leading to earlier Irish availability of targeted therapies for autoimmune and gastrointestinal diseases, supporting unmet medical needs and broadening Teva’s relevance within the Irish market landscape.

Teva’s technical indicators, as of late May 2025, show a broadly neutral stance with positive bias, supported by buy signals on several key moving averages. Specifically, the 5-day, 50-day, 100-day, and 200-day moving averages all point to buy conditions, while the MACD remains positive. The company’s Relative Strength Index (RSI) hovers near 49, suggesting neither overbought nor oversold status, with the stochastic oscillator in the oversold zone. These signals, together with a consensus analyst target price of approximately $23.12 (+30% upside from current levels), provide a constructive technical and sentiment framework relevant for Irish institutional investors seeking entry points or portfolio allocation adjustments.

Teva continues to deepen its engagement with the Irish market through substantial generic and biosimilar product distribution, supporting the HSE’s cost-containment priorities and patient access objectives. Operating in Ireland via integrated supply chains and direct sales channels, Teva secures its position as one of the primary contributors to national medicine savings, with a particular emphasis on chronic disease therapies. Expansion in biosimilars—now 18 assets in the pipeline—aligns with ongoing shifts in Irish health policy toward sustainable access and budget predictability, bolstering Teva’s strategic presence and dimming long-term competitive risks.

FAQ

What is the latest dividend for Teva Pharmaceuticals stock?

Teva Pharmaceuticals does not currently pay a dividend to shareholders. The company suspended its dividend several years ago as part of a broader financial restructuring and has not indicated plans to resume payouts in the near term. Historically, Teva was a regular dividend payer but has focused recent cash flows on reducing debt and investing in its growing product pipeline.

What is the forecast for Teva Pharmaceuticals stock in 2025, 2026, and 2027?

Based on the latest share price of $17.53, forecasts indicate a value of $22.78 by the end of 2025, $26.30 by the end of 2026, and $35.06 by the end of 2027. These optimistic projections reflect Teva’s ongoing transformation, solid innovation pipeline, and strong presence in both specialty and generic medicines, supported by recent analyst upgrades and robust revenue outlook.

Should I sell my Teva Pharmaceuticals shares?

It may be worthwhile to hold Teva Pharmaceuticals shares given the current valuation and ongoing recovery. The company has demonstrated nine consecutive quarters of growth and is benefitting from innovation in its specialty drug and biosimilar segments. While debt remains a consideration, Teva’s global reach and successful strategic pivot enhance its mid- to long-term growth prospects, making continued holding potentially attractive for investors seeking exposure to the pharmaceutical sector’s momentum.

How are Teva Pharmaceuticals stock dividends and capital gains taxed in Ireland?

As an Irish resident, dividends from Teva Pharmaceuticals (a US-listed stock) are generally subject to US withholding tax, typically at 15% with correct forms, and are taxed as income in Ireland. Capital gains are taxed at Ireland’s standard rate for gains (currently 33%). Teva does not currently pay a dividend, but for any future distributions or gains, offset or credits for US withholding may be available depending on your tax position.

What is the latest dividend for Teva Pharmaceuticals stock?

Teva Pharmaceuticals does not currently pay a dividend to shareholders. The company suspended its dividend several years ago as part of a broader financial restructuring and has not indicated plans to resume payouts in the near term. Historically, Teva was a regular dividend payer but has focused recent cash flows on reducing debt and investing in its growing product pipeline.

What is the forecast for Teva Pharmaceuticals stock in 2025, 2026, and 2027?

Based on the latest share price of $17.53, forecasts indicate a value of $22.78 by the end of 2025, $26.30 by the end of 2026, and $35.06 by the end of 2027. These optimistic projections reflect Teva’s ongoing transformation, solid innovation pipeline, and strong presence in both specialty and generic medicines, supported by recent analyst upgrades and robust revenue outlook.

Should I sell my Teva Pharmaceuticals shares?

It may be worthwhile to hold Teva Pharmaceuticals shares given the current valuation and ongoing recovery. The company has demonstrated nine consecutive quarters of growth and is benefitting from innovation in its specialty drug and biosimilar segments. While debt remains a consideration, Teva’s global reach and successful strategic pivot enhance its mid- to long-term growth prospects, making continued holding potentially attractive for investors seeking exposure to the pharmaceutical sector’s momentum.

How are Teva Pharmaceuticals stock dividends and capital gains taxed in Ireland?

As an Irish resident, dividends from Teva Pharmaceuticals (a US-listed stock) are generally subject to US withholding tax, typically at 15% with correct forms, and are taxed as income in Ireland. Capital gains are taxed at Ireland’s standard rate for gains (currently 33%). Teva does not currently pay a dividend, but for any future distributions or gains, offset or credits for US withholding may be available depending on your tax position.

On the same topic

Should I buy Bed Bath & Beyond stock in 2025? Advice for Irish Investors
30 May 2025
Read the article
Should I Buy BigCommerce Stock in 2025? A Complete Guide for Ireland
1 June 2025
Read the article
Should I buy Wells Fargo stock in 2025?
30 May 2025
Read the article
Should I buy Kenmare Resources stock in 2025?
30 May 2025
Read the article
Should I buy GE Vernova stock in 2025? (Ireland Advice)
30 May 2025
Read the article
Should I buy Cairn Homes stock in 2025?
30 May 2025
Read the article
Should I buy Salesforce stock in 2025?
30 May 2025
Read the article
Should I buy Ferrari stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I buy AstraZeneca stock in 2025?
30 May 2025
Read the article
Should I buy JD.com stock in 2025?
30 May 2025
Read the article
Should I buy Denison Mines stock in 2025?
30 May 2025
Read the article
Should I buy Apple stock in 2025?
30 May 2025
Read the article
Should I Buy AMC Stock in 2025? Comprehensive Analysis for Ireland
30 May 2025
Read the article
Should I buy ESS Tech stock in 2025?
30 May 2025
Read the article
Should I buy Marathon Petroleum stock in 2025? Essential Guide for Irish Investors
30 May 2025
Read the article
Should I buy Square stock in 2025?
30 May 2025
Read the article
Should I Buy Moderna Stock in 2025? Complete Ireland Analysis
30 May 2025
Read the article
Should I Buy Cresco Labs Stock in 2025? Expert Guide for Ireland
30 May 2025
Read the article
Should I Buy Varta Stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I buy UiPath stock in 2025? A guide for investors in Ireland
1 June 2025
Read the article
Should I buy Delta Air Lines stock in 2025?
30 May 2025
Read the article
Should I buy Kerry Group stock in 2025?
30 May 2025
Read the article
Should I buy Bionano Genomics stock in 2025?
30 May 2025
Read the article
Should I buy SoFi stock in 2025?
30 May 2025
Read the article
Should I buy Intel stock in 2025? Ireland Edition
30 May 2025
Read the article
Should I buy Super Micro Computer stock in 2025?
30 May 2025
Read the article
Should you buy Sundial Growers stock in 2025? Expert advice for Ireland
30 May 2025
Read the article
Should I buy Tian Ruixiang stock in 2025?
30 May 2025
Read the article
Should I buy Party City stock in 2025?
30 May 2025
Read the article
Should I buy AIB Group stock in 2025?
30 May 2025
Read the article
Should I buy Affirm stock in 2025? (Ireland Edition)
30 May 2025
Read the article
Should I buy Analog Devices stock in 2025? Full Analysis for Ireland
30 May 2025
Read the article
Should I buy Cosmos Health stock in 2025? Comprehensive Guide for Irish Investors
30 May 2025
Read the article
Should I buy TD Bank stock in 2025?
30 May 2025
Read the article
Should I Buy Glanbia Stock in 2025? Expert Analysis for Ireland
30 May 2025
Read the article
Should I buy Walmart stock in 2025? A guide for investors in Ireland
30 May 2025
Read the article
Should I buy Sanofi stock in 2025?
30 May 2025
Read the article
Should I buy Citigroup stock in 2025?
30 May 2025
Read the article
Should I buy Palantir stock in 2025?
30 May 2025
Read the article
Should I Buy Groupon Stock in 2025? Expert Guide for Ireland
30 May 2025
Read the article
Should I buy Maersk stock in 2025?
30 May 2025
Read the article
Should I buy IonQ stock in Ireland in 2025?
30 May 2025
Read the article
Should I Buy Airbnb Stock in 2025? Analysis for Irish Investors
30 May 2025
Read the article
Should I buy Permanent TSB stock in 2025?
30 May 2025
Read the article
Should I buy Acadia Pharmaceuticals stock in 2025?
30 May 2025
Read the article
Should I buy Volkswagen stock in 2025? Expert Guide for Irish Investors
30 May 2025
Read the article
Should I buy Workhorse stock in 2025?
30 May 2025
Read the article
Should you buy BYD stock in 2025? Complete guide for Ireland
30 May 2025
Read the article
Should I Buy Nestlé Stock in Ireland in 2025?
30 May 2025
Read the article
Should I buy Toast stock in 2025? Expert Guide for Irish Investors
30 May 2025
Read the article
Should I buy Archer-Daniels-Midland stock in 2025? Expert Advice for Investors in Ireland
30 May 2025
Read the article
Should I buy MEI Pharma stock in 2025?
30 May 2025
Read the article
Should I buy Chipotle stock in 2025?
30 May 2025
Read the article
Should I buy Nikola stock in 2025?
30 May 2025
Read the article
Should I buy CLS Holdings stock in 2025? Expert Advice for Investors in Ireland
30 May 2025
Read the article
Should I buy Canopy Growth stock in 2025?
30 May 2025
Read the article
Should I buy Boohoo stock in 2025?
30 May 2025
Read the article
Should I buy New Era Helium stock in 2025? Expert Guide for Irish Investors
30 May 2025
Read the article
Should I buy PDD Holdings stock in 2025?
30 May 2025
Read the article
Should I Buy Johnson Controls Stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I buy Dominion Energy stock in 2025?
30 May 2025
Read the article
Should I buy Glencore stock in 2025?
30 May 2025
Read the article
Should I buy Ambev stock in 2025? Full Guide for Ireland
30 May 2025
Read the article
Should I buy Microsoft stock in 2025?
30 May 2025
Read the article
Should I buy Hasbro stock in 2025 as an investor in Ireland?
30 May 2025
Read the article
Should I buy Black Rifle Coffee Company stock in 2025? A Guide for Ireland
30 May 2025
Read the article
Should I buy Organon stock in 2025?
30 May 2025
Read the article
Should I buy Alpine 4 Holdings stock in 2025? Essential insights for Ireland
30 May 2025
Read the article
Should I buy Accenture stock in 2025?
30 May 2025
Read the article
Should I buy Rocket Lab stock in 2025? The Essential Guide for Ireland
30 May 2025
Read the article
Should I buy Lightbridge stock in 2025?
30 May 2025
Read the article
Should I buy LATAM Airlines stock in 2025?
30 May 2025
Read the article
Should I buy Umicore stock in 2025? Complete Analysis for Irish Investors
30 May 2025
Read the article
Should I Buy Kroger Stock in 2025? Expert Advice for Irish Investors
30 May 2025
Read the article
Should I buy GoTo Gojek Tokopedia stock in 2025?
30 May 2025
Read the article
Should I buy Applied Therapeutics stock in 2025?
30 May 2025
Read the article
Should I Buy Genius Brands Stock in Ireland in 2025?
30 May 2025
Read the article
Should I buy Smurfit Kappa stock in 2025?
30 May 2025
Read the article
Should I buy The Honest Company stock in 2025?
30 May 2025
Read the article
Should I buy PubMatic stock in 2025?
30 May 2025
Read the article
Should I Buy Pfizer Stock in 2025? Full Irish Market Analysis
30 May 2025
Read the article
Should I buy Origin Enterprises stock in 2025?
30 May 2025
Read the article
Should I buy Dalata Hotel Group stock in 2025?
30 May 2025
Read the article
Should I buy PepsiCo stock in 2025? Key Insights for Irish Investors
30 May 2025
Read the article
Should I buy Nike stock in 2025?
30 May 2025
Read the article
Should I buy Kingspan Group stock in 2025?
30 May 2025
Read the article
Should I buy Castor Maritime stock in 2025?
30 May 2025
Read the article
Should I buy BlackBerry stock in 2025? Your guide for Ireland
30 May 2025
Read the article
Should I buy Capital One stock in 2025? Complete guide for Irish investors
30 May 2025
Read the article
Should I buy Alpha and Omega Semiconductor stock in 2025? Expert Insights for Ireland
30 May 2025
Read the article
Should I buy Micron Technology stock in 2025?
30 May 2025
Read the article
Should I buy Amazon stock in 2025? Insights for Irish Investors
30 May 2025
Read the article
Should I buy Novo Nordisk stock in 2025?
30 May 2025
Read the article
Should I buy Roche stock in 2025?
30 May 2025
Read the article
Should I Buy Alteryx Stock in 2025? Key Insights for Ireland
30 May 2025
Read the article
Should I buy Ryanair stock in 2025?
30 May 2025
Read the article
Should I Buy Dexcom Stock in 2025? Expert Analysis for Ireland
30 May 2025
Read the article
Should I buy Tellurian stock in 2025?
30 May 2025
Read the article
Should I buy MercadoLibre stock in 2025?
30 May 2025
Read the article
Should I buy Nuvve stock in 2025?
30 May 2025
Read the article
Should I buy Procter & Gamble stock in 2025?
30 May 2025
Read the article
Should I buy Siemens Energy stock in 2025?
30 May 2025
Read the article
Should I buy Nvidia stock in 2025?
30 May 2025
Read the article
Should I buy Guess stock in 2025? Expert Insights for Irish Investors
30 May 2025
Read the article
Should I buy BioCryst stock in 2025?
30 May 2025
Read the article
Should I Buy Boston Scientific Stock in 2025? Advice for Irish Investors
30 May 2025
Read the article
Should I buy Lemonade stock in 2025?
30 May 2025
Read the article
Should I Buy Tesla Stock in 2025? A Guide for Investors in Ireland
30 May 2025
Read the article
Should I buy Greencoat Renewables stock in 2025?
30 May 2025
Read the article
Should I buy Qualcomm stock in 2025?
30 May 2025
Read the article
Should I buy Glenveagh Properties stock in 2025?
30 May 2025
Read the article
Should I Buy Marathon Oil Stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I buy Red Hat stock in 2025?
30 May 2025
Read the article
Should I buy Johnson & Johnson stock in 2025?
30 May 2025
Read the article
Should I buy Schwab U.S. Dividend Equity ETF stock in 2025?
30 May 2025
Read the article
Should I buy Penn Entertainment stock in 2025?
30 May 2025
Read the article
Should I buy Cleveland-Cliffs stock in 2025?
30 May 2025
Read the article
Should I Buy Regeneron Stock in 2025? Expert Guide for Ireland
30 May 2025
Read the article
Should I buy Disney stock in 2025? Full Analysis for Irish Investors
30 May 2025
Read the article
Should I buy NIO stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I Buy Momo Stock in 2025? Expert Guide for Ireland
30 May 2025
Read the article
Should I Buy Vaxart Stock in 2025? Analysis for Irish Investors
30 May 2025
Read the article
Should I Buy AMD Stock in 2025? Expert Analysis for Investors in Ireland
30 May 2025
Read the article
Should I buy FBD Holdings stock in 2025?
30 May 2025
Read the article
Should I buy Matterport stock in 2025?
30 May 2025
Read the article
Should I buy EMCORE stock in 2025?
30 May 2025
Read the article
Should I buy Bayer stock in 2025? Expert Advice for Ireland
30 May 2025
Read the article
Should I buy 3M stock in 2025? Full Guide for Ireland
30 May 2025
Read the article
Should I buy Dell stock in 2025? Expert Analysis for Ireland
30 May 2025
Read the article
Should I buy IBM stock in 2025?
30 May 2025
Read the article
Should I buy U.S. Bancorp stock in 2025?
30 May 2025
Read the article
Should I buy CrowdStrike stock in 2025?
30 May 2025
Read the article
Should I buy GameStop stock in 2025? A Complete Guide for Ireland
30 May 2025
Read the article
Should I buy Neo stock in 2025?
30 May 2025
Read the article
Should I buy Matinas BioPharma stock in 2025?
30 May 2025
Read the article
Should I buy GitLab stock in 2025? Insights for Irish Investors
30 May 2025
Read the article
Should I buy Qualtrics stock in 2025? Insights for Ireland
30 May 2025
Read the article
Should I buy Irish Residential Properties REIT stock in 2025?
30 May 2025
Read the article
Should I buy Uniphar stock in 2025? Analysis for Irish investors
30 May 2025
Read the article
Should I buy GoldMining stock in 2025?
30 May 2025
Read the article
Should I buy Mastercard stock in 2025?
30 May 2025
Read the article
Should I buy Viatris stock in 2025?
30 May 2025
Read the article
Should I buy Ford stock in 2025?
30 May 2025
Read the article
Should I buy Coinbase stock in 2025?
30 May 2025
Read the article
Should I buy Mullen Automotive stock in 2025?
30 May 2025
Read the article
Should I buy Alphabet stock in 2025?
30 May 2025
Read the article
Should I buy Malin Corporation stock in 2025?
30 May 2025
Read the article
Should I Buy Snap Stock in 2025? Expert Guide for Ireland
30 May 2025
Read the article
Should I buy Carnival stock in 2025? A Complete Guide for Irish Investors
30 May 2025
Read the article
Should I buy FD Technologies stock in 2025?
30 May 2025
Read the article
Should I buy Abbott Laboratories stock in 2025?
30 May 2025
Read the article
Should I buy Global X Cannabis ETF stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I Buy Arrival Stock in 2025? Expert Insights for Irish Investors
30 May 2025
Read the article
Should I buy Irish Continental Group stock in 2025?
30 May 2025
Read the article
Should I buy Datadog stock in 2025?
30 May 2025
Read the article
Should I Buy Baidu Stock in 2025? Expert Irish Market Analysis
30 May 2025
Read the article
Should I buy Lufthansa stock in 2025?
30 May 2025
Read the article
Should I buy Diageo stock in 2025?
30 May 2025
Read the article
Should I buy Cano Health stock in 2025?
30 May 2025
Read the article
Should I invest in Lucid Group stock in 2025?
30 May 2025
Read the article
Should I buy ServiceMaster stock in 2025? Expert Advice for IE Investors
30 May 2025
Read the article
Should I buy Bristol Myers Squibb stock in 2025?
30 May 2025
Read the article
Should I buy Bank of Ireland stock in 2025?
30 May 2025
Read the article
Should I buy DocuSign stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I buy Riot Platforms stock in 2025?
30 May 2025
Read the article
Should I buy Nu Holdings stock in 2025?
30 May 2025
Read the article
Should I buy StoneCo stock in 2025? (Ireland Edition)
30 May 2025
Read the article
Should I buy Bed Bath & Beyond stock in 2025? Advice for Irish Investors
30 May 2025
Read the article
Should I Buy BigCommerce Stock in 2025? A Complete Guide for Ireland
1 June 2025
Read the article
Should I buy Wells Fargo stock in 2025?
30 May 2025
Read the article
Should I buy Kenmare Resources stock in 2025?
30 May 2025
Read the article
Should I buy GE Vernova stock in 2025? (Ireland Advice)
30 May 2025
Read the article
Should I buy Cairn Homes stock in 2025?
30 May 2025
Read the article
Should I buy Salesforce stock in 2025?
30 May 2025
Read the article
Should I buy Ferrari stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I buy AstraZeneca stock in 2025?
30 May 2025
Read the article
Should I buy JD.com stock in 2025?
30 May 2025
Read the article
Should I buy Denison Mines stock in 2025?
30 May 2025
Read the article
Should I buy Apple stock in 2025?
30 May 2025
Read the article
Should I Buy AMC Stock in 2025? Comprehensive Analysis for Ireland
30 May 2025
Read the article
Should I buy ESS Tech stock in 2025?
30 May 2025
Read the article
Should I buy Marathon Petroleum stock in 2025? Essential Guide for Irish Investors
30 May 2025
Read the article
Should I buy Square stock in 2025?
30 May 2025
Read the article
Should I Buy Moderna Stock in 2025? Complete Ireland Analysis
30 May 2025
Read the article
Should I Buy Cresco Labs Stock in 2025? Expert Guide for Ireland
30 May 2025
Read the article
Should I Buy Varta Stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I buy UiPath stock in 2025? A guide for investors in Ireland
1 June 2025
Read the article
Should I buy Delta Air Lines stock in 2025?
30 May 2025
Read the article
Should I buy Kerry Group stock in 2025?
30 May 2025
Read the article
Should I buy Bionano Genomics stock in 2025?
30 May 2025
Read the article
Should I buy SoFi stock in 2025?
30 May 2025
Read the article
Should I buy Intel stock in 2025? Ireland Edition
30 May 2025
Read the article
Should I buy Super Micro Computer stock in 2025?
30 May 2025
Read the article
Should you buy Sundial Growers stock in 2025? Expert advice for Ireland
30 May 2025
Read the article
Should I buy Tian Ruixiang stock in 2025?
30 May 2025
Read the article
Should I buy Party City stock in 2025?
30 May 2025
Read the article
Should I buy AIB Group stock in 2025?
30 May 2025
Read the article
Should I buy Affirm stock in 2025? (Ireland Edition)
30 May 2025
Read the article
Should I buy Analog Devices stock in 2025? Full Analysis for Ireland
30 May 2025
Read the article
Should I buy Cosmos Health stock in 2025? Comprehensive Guide for Irish Investors
30 May 2025
Read the article
Should I buy TD Bank stock in 2025?
30 May 2025
Read the article
Should I Buy Glanbia Stock in 2025? Expert Analysis for Ireland
30 May 2025
Read the article
Should I buy Walmart stock in 2025? A guide for investors in Ireland
30 May 2025
Read the article
Should I buy Sanofi stock in 2025?
30 May 2025
Read the article
Should I buy Citigroup stock in 2025?
30 May 2025
Read the article
Should I buy Palantir stock in 2025?
30 May 2025
Read the article
Should I Buy Groupon Stock in 2025? Expert Guide for Ireland
30 May 2025
Read the article
Should I buy Maersk stock in 2025?
30 May 2025
Read the article
Should I buy IonQ stock in Ireland in 2025?
30 May 2025
Read the article
Should I Buy Airbnb Stock in 2025? Analysis for Irish Investors
30 May 2025
Read the article
Should I buy Permanent TSB stock in 2025?
30 May 2025
Read the article
Should I buy Acadia Pharmaceuticals stock in 2025?
30 May 2025
Read the article
Should I buy Volkswagen stock in 2025? Expert Guide for Irish Investors
30 May 2025
Read the article
Should I buy Workhorse stock in 2025?
30 May 2025
Read the article
Should you buy BYD stock in 2025? Complete guide for Ireland
30 May 2025
Read the article
Should I Buy Nestlé Stock in Ireland in 2025?
30 May 2025
Read the article
Should I buy Toast stock in 2025? Expert Guide for Irish Investors
30 May 2025
Read the article
Should I buy Archer-Daniels-Midland stock in 2025? Expert Advice for Investors in Ireland
30 May 2025
Read the article
Should I buy MEI Pharma stock in 2025?
30 May 2025
Read the article
Should I buy Chipotle stock in 2025?
30 May 2025
Read the article
Should I buy Nikola stock in 2025?
30 May 2025
Read the article
Should I buy CLS Holdings stock in 2025? Expert Advice for Investors in Ireland
30 May 2025
Read the article
Should I buy Canopy Growth stock in 2025?
30 May 2025
Read the article
Should I buy Boohoo stock in 2025?
30 May 2025
Read the article
Should I buy New Era Helium stock in 2025? Expert Guide for Irish Investors
30 May 2025
Read the article
Should I buy PDD Holdings stock in 2025?
30 May 2025
Read the article
Should I Buy Johnson Controls Stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I buy Dominion Energy stock in 2025?
30 May 2025
Read the article
Should I buy Glencore stock in 2025?
30 May 2025
Read the article
Should I buy Ambev stock in 2025? Full Guide for Ireland
30 May 2025
Read the article
Should I buy Microsoft stock in 2025?
30 May 2025
Read the article
Should I buy Hasbro stock in 2025 as an investor in Ireland?
30 May 2025
Read the article
Should I buy Black Rifle Coffee Company stock in 2025? A Guide for Ireland
30 May 2025
Read the article
Should I buy Organon stock in 2025?
30 May 2025
Read the article
Should I buy Alpine 4 Holdings stock in 2025? Essential insights for Ireland
30 May 2025
Read the article
Should I buy Accenture stock in 2025?
30 May 2025
Read the article
Should I buy Rocket Lab stock in 2025? The Essential Guide for Ireland
30 May 2025
Read the article
Should I buy Lightbridge stock in 2025?
30 May 2025
Read the article
Should I buy LATAM Airlines stock in 2025?
30 May 2025
Read the article
Should I buy Umicore stock in 2025? Complete Analysis for Irish Investors
30 May 2025
Read the article
Should I Buy Kroger Stock in 2025? Expert Advice for Irish Investors
30 May 2025
Read the article
Should I buy GoTo Gojek Tokopedia stock in 2025?
30 May 2025
Read the article
Should I buy Applied Therapeutics stock in 2025?
30 May 2025
Read the article
Should I Buy Genius Brands Stock in Ireland in 2025?
30 May 2025
Read the article
Should I buy Smurfit Kappa stock in 2025?
30 May 2025
Read the article
Should I buy The Honest Company stock in 2025?
30 May 2025
Read the article
Should I buy PubMatic stock in 2025?
30 May 2025
Read the article
Should I Buy Pfizer Stock in 2025? Full Irish Market Analysis
30 May 2025
Read the article
Should I buy Origin Enterprises stock in 2025?
30 May 2025
Read the article
Should I buy Dalata Hotel Group stock in 2025?
30 May 2025
Read the article
Should I buy PepsiCo stock in 2025? Key Insights for Irish Investors
30 May 2025
Read the article
Should I buy Nike stock in 2025?
30 May 2025
Read the article
Should I buy Kingspan Group stock in 2025?
30 May 2025
Read the article
Should I buy Castor Maritime stock in 2025?
30 May 2025
Read the article
Should I buy BlackBerry stock in 2025? Your guide for Ireland
30 May 2025
Read the article
Should I buy Capital One stock in 2025? Complete guide for Irish investors
30 May 2025
Read the article
Should I buy Alpha and Omega Semiconductor stock in 2025? Expert Insights for Ireland
30 May 2025
Read the article
Should I buy Micron Technology stock in 2025?
30 May 2025
Read the article
Should I buy Amazon stock in 2025? Insights for Irish Investors
30 May 2025
Read the article
Should I buy Novo Nordisk stock in 2025?
30 May 2025
Read the article
Should I buy Roche stock in 2025?
30 May 2025
Read the article
Should I Buy Alteryx Stock in 2025? Key Insights for Ireland
30 May 2025
Read the article
Should I buy Ryanair stock in 2025?
30 May 2025
Read the article
Should I Buy Dexcom Stock in 2025? Expert Analysis for Ireland
30 May 2025
Read the article
Should I buy Tellurian stock in 2025?
30 May 2025
Read the article
Should I buy MercadoLibre stock in 2025?
30 May 2025
Read the article
Should I buy Nuvve stock in 2025?
30 May 2025
Read the article
Should I buy Procter & Gamble stock in 2025?
30 May 2025
Read the article
Should I buy Siemens Energy stock in 2025?
30 May 2025
Read the article
Should I buy Nvidia stock in 2025?
30 May 2025
Read the article
Should I buy Guess stock in 2025? Expert Insights for Irish Investors
30 May 2025
Read the article
Should I buy BioCryst stock in 2025?
30 May 2025
Read the article
Should I Buy Boston Scientific Stock in 2025? Advice for Irish Investors
30 May 2025
Read the article
Should I buy Lemonade stock in 2025?
30 May 2025
Read the article
Should I Buy Tesla Stock in 2025? A Guide for Investors in Ireland
30 May 2025
Read the article
Should I buy Greencoat Renewables stock in 2025?
30 May 2025
Read the article
Should I buy Qualcomm stock in 2025?
30 May 2025
Read the article
Should I buy Glenveagh Properties stock in 2025?
30 May 2025
Read the article
Should I Buy Marathon Oil Stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I buy Red Hat stock in 2025?
30 May 2025
Read the article
Should I buy Johnson & Johnson stock in 2025?
30 May 2025
Read the article
Should I buy Schwab U.S. Dividend Equity ETF stock in 2025?
30 May 2025
Read the article
Should I buy Penn Entertainment stock in 2025?
30 May 2025
Read the article
Should I buy Cleveland-Cliffs stock in 2025?
30 May 2025
Read the article
Should I Buy Regeneron Stock in 2025? Expert Guide for Ireland
30 May 2025
Read the article
Should I buy Disney stock in 2025? Full Analysis for Irish Investors
30 May 2025
Read the article
Should I buy NIO stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I Buy Momo Stock in 2025? Expert Guide for Ireland
30 May 2025
Read the article
Should I Buy Vaxart Stock in 2025? Analysis for Irish Investors
30 May 2025
Read the article
Should I Buy AMD Stock in 2025? Expert Analysis for Investors in Ireland
30 May 2025
Read the article
Should I buy FBD Holdings stock in 2025?
30 May 2025
Read the article
Should I buy Matterport stock in 2025?
30 May 2025
Read the article
Should I buy EMCORE stock in 2025?
30 May 2025
Read the article
Should I buy Bayer stock in 2025? Expert Advice for Ireland
30 May 2025
Read the article
Should I buy 3M stock in 2025? Full Guide for Ireland
30 May 2025
Read the article
Should I buy Dell stock in 2025? Expert Analysis for Ireland
30 May 2025
Read the article
Should I buy IBM stock in 2025?
30 May 2025
Read the article
Should I buy U.S. Bancorp stock in 2025?
30 May 2025
Read the article
Should I buy CrowdStrike stock in 2025?
30 May 2025
Read the article
Should I buy GameStop stock in 2025? A Complete Guide for Ireland
30 May 2025
Read the article
Should I buy Neo stock in 2025?
30 May 2025
Read the article
Should I buy Matinas BioPharma stock in 2025?
30 May 2025
Read the article
Should I buy GitLab stock in 2025? Insights for Irish Investors
30 May 2025
Read the article
Should I buy Qualtrics stock in 2025? Insights for Ireland
30 May 2025
Read the article
Should I buy Irish Residential Properties REIT stock in 2025?
30 May 2025
Read the article
Should I buy Uniphar stock in 2025? Analysis for Irish investors
30 May 2025
Read the article
Should I buy GoldMining stock in 2025?
30 May 2025
Read the article
Should I buy Mastercard stock in 2025?
30 May 2025
Read the article
Should I buy Viatris stock in 2025?
30 May 2025
Read the article
Should I buy Ford stock in 2025?
30 May 2025
Read the article
Should I buy Coinbase stock in 2025?
30 May 2025
Read the article
Should I buy Mullen Automotive stock in 2025?
30 May 2025
Read the article
Should I buy Alphabet stock in 2025?
30 May 2025
Read the article
Should I buy Malin Corporation stock in 2025?
30 May 2025
Read the article
Should I Buy Snap Stock in 2025? Expert Guide for Ireland
30 May 2025
Read the article
Should I buy Carnival stock in 2025? A Complete Guide for Irish Investors
30 May 2025
Read the article
Should I buy FD Technologies stock in 2025?
30 May 2025
Read the article
Should I buy Abbott Laboratories stock in 2025?
30 May 2025
Read the article
Should I buy Global X Cannabis ETF stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I Buy Arrival Stock in 2025? Expert Insights for Irish Investors
30 May 2025
Read the article
Should I buy Irish Continental Group stock in 2025?
30 May 2025
Read the article
Should I buy Datadog stock in 2025?
30 May 2025
Read the article
Should I Buy Baidu Stock in 2025? Expert Irish Market Analysis
30 May 2025
Read the article
Should I buy Lufthansa stock in 2025?
30 May 2025
Read the article
Should I buy Diageo stock in 2025?
30 May 2025
Read the article
Should I buy Cano Health stock in 2025?
30 May 2025
Read the article
Should I invest in Lucid Group stock in 2025?
30 May 2025
Read the article
Should I buy ServiceMaster stock in 2025? Expert Advice for IE Investors
30 May 2025
Read the article
Should I buy Bristol Myers Squibb stock in 2025?
30 May 2025
Read the article
Should I buy Bank of Ireland stock in 2025?
30 May 2025
Read the article
Should I buy DocuSign stock in 2025? Complete Guide for Ireland
30 May 2025
Read the article
Should I buy Riot Platforms stock in 2025?
30 May 2025
Read the article
Should I buy Nu Holdings stock in 2025?
30 May 2025
Read the article
Should I buy StoneCo stock in 2025? (Ireland Edition)
30 May 2025
Read the article
P. Laurore
P. Laurore
Finance expert
HelloSafe
Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.

Ask a question, an expert will answer